Spots Global Cancer Trial Database for reparixin
Every month we try and update this database with for reparixin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer | NCT05212701 | Fatigue Locally Advance... | Reparixin Placebo | 18 Years - | Dompé Farmaceutici S.p.A | |
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | NCT05835466 | Myelofibrosis (... Post Essential ... Post Polycythem... | reparixin | 18 Years - | Icahn School of Medicine at Mount Sinai | |
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | NCT02370238 | Metastatic Brea... | paclitaxel Reparixin placebo | 18 Years - | Dompé Farmaceutici S.p.A | |
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | NCT02370238 | Metastatic Brea... | paclitaxel Reparixin placebo | 18 Years - | Dompé Farmaceutici S.p.A | |
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer | NCT05212701 | Fatigue Locally Advance... | Reparixin Placebo | 18 Years - | Dompé Farmaceutici S.p.A | |
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer | NCT05212701 | Fatigue Locally Advance... | Reparixin Placebo | 18 Years - | Dompé Farmaceutici S.p.A | |
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer | NCT02370238 | Metastatic Brea... | paclitaxel Reparixin placebo | 18 Years - | Dompé Farmaceutici S.p.A |